hVIVO plc (AIM: HVO), a contract research organisation specialising in infectious and respiratory disease trials, announced on Monday that it has completed a successful pilot characterisation study for its human metapneumovirus (hMPV) challenge model.
Conducted at its advanced quarantine facility in Canary Wharf, the study demonstrated a strong infectivity rate and symptomatic disease in healthy volunteers, confirming the feasibility of the hMPV model for testing vaccines and antivirals.
The company is now marketing its hMPV challenge model, targeting future human challenge trials to support the development of much-needed treatments for hMPV. Plans are underway to complete the characterisation study with a partner.
Dr Andrew Catchpole, Chief Scientific Officer at hVIVO, will present findings from the pilot study at the 13th International RSV Symposium in Brazil from 12-15 March 2025.
hVIVO operates the world's largest commercial human challenge trial facility in London and provides an end-to-end suite of services, including drug development consultancy, challenge agent manufacturing, and specialised virology and immunology testing through its Venn Life Sciences and hLAB brands.
Human metapneumovirus is a prevalent respiratory pathogen causing symptoms similar to the common cold but can lead to severe complications, including pneumonia and bronchiolitis, particularly in young children. Despite its global impact, there are currently no approved vaccines or antiviral treatments for hMPV.
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
ANGLE plc reports successful dual CTC-DNA and ctDNA analysis using Illumina platform
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Vast Therapeutics receives USD2m grant from National Institutes of Health
Nanobiotix reports first patient dosed in Phase 2 lung cancer study
AstraZeneca's Datroway approved in US for HR-positive breast cancer
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
bioAffinity Technologies declares successful beta launch of CyPath Lung in Texas